Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non
- PDF / 723,766 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 61 Downloads / 152 Views
ORIGINAL RESEARCH
Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer Dong Ding . Huabin Hu . Mengting Liao . Yin Shi . Longjiang She . Linli Yao . Youwen Zhu . Shan Zeng . Jin Huang
Received: February 9, 2020 Ó Springer Healthcare Ltd., part of Springer Nature 2020
ABSTRACT Introduction: The purpose of this study was to estimate the cost-effectiveness of atezolizumab plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the United States (US) payers’ perspective in the first-line treatment.
The authors Dong Ding and Huabin Hu contributed equally to this work.
Digital features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.11955858. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12325020-01292-3) contains supplementary material, which is available to authorized users. D. Ding L. She L. Yao Y. Zhu S. Zeng J. Huang (&) Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China e-mail: [email protected] H. Hu Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China H. Hu Guangdong Institute of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou 510655, China
Methods: A mathematical Markov model was developed to estimate cost and effectiveness of atezolizumab combination therapy versus carboplatin plus nab-paclitaxel alone in the firstline therapy of metastatic non-squamous NSCLC from the data of IMpower130. Costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were analyzed, and model robustness was assessed by sensitivity analysis. Additional subgroup analyses were performed as well. Results: Compared to chemotherapy, treatment with atezolizumab plus chemotherapy yields an increase of 0.16 QALYs with an increase in cost of $109,809.13, resulting in an ICER of $670,309.66 per QALY. The most influential factor in this model was the cost of atezolizumab. Probabilistic sensitivity analysis showed that there was 0% probability that atezolizumab plus chemotherapy was cost-effective M. Liao Department of Health Management Center, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China Y. Shi Department of Pharmacy, Xiangya Hospital Central South University, Changsha 410008, Hunan, China
Adv Ther
at willingness-to-pay (WTP) values of $150,000 per QALY. The results of subgroup analyses showed that the ICER remained greater than $150,000/QALY across the all patient subgroups. Conclusion: First-line treatment with atezolizumab in combination with carboplatin plus nab-paclitaxel is not a cost-effective option in patients with metastatic non-squamous NSCLC. Keywords: Atezolizumab; Cost-effectiveness; Non-small cell lung cancer; Oncology Key Summary Points Why carry out this study? Atezoliz
Data Loading...
